Boston Scientific Corporation (NYSE:BSX) Holdings Decreased by NBW Capital LLC

Key Points

• NBW Capital LLC reduced its stake in Boston Scientific Corporation by 48.2% in the first quarter, bringing its holdings down to 52,200 shares valued at approximately $5.27 million.
• Multiple institutional investors have recently increased their positions in Boston Scientific, with Colonial Trust Co SC boosting its holdings by 1,625.0% in the fourth quarter.
• Analysts have varied opinions on the stock, with twenty-two rating it a buy, three giving it a strong buy, and the consensus rating being "Buy" with an average price target of $117.50.

NBW Capital LLC trimmed its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 48.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,200 shares of the medical equipment provider's stock after selling 48,658 shares during the quarter. NBW Capital LLC's holdings in Boston Scientific were worth $5,266,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also bought and sold shares of BSX. NS Partners Ltd boosted its holdings in shares of Boston Scientific by 1.6% in the first quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider's stock worth $37,143,000 after buying an additional 5,704 shares during the last quarter. LaSalle St. Investment Advisors LLC increased its stake in Boston Scientific by 12.4% in the first quarter. LaSalle St. Investment Advisors LLC now owns 3,585 shares of the medical equipment provider's stock worth $361,000 after purchasing an additional 395 shares during the period. Fayez Sarofim & Co boosted its stake in shares of Boston Scientific by 5.4% during the first quarter. Fayez Sarofim & Co now owns 5,641 shares of the medical equipment provider's stock valued at $569,000 after purchasing an additional 290 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Boston Scientific by 12.7% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,631,512 shares of the medical equipment provider's stock worth $265,467,000 after acquiring an additional 295,658 shares during the period. Finally, Y.D. More Investments Ltd purchased a new stake in Boston Scientific in the first quarter worth about $27,000. 89.07% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have commented on BSX. Citigroup reissued a "buy" rating and set a $125.00 price target (up from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Evercore ISI increased their target price on Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a research report on Thursday, April 24th. Leerink Partnrs upgraded Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Erste Group Bank raised Boston Scientific to a "strong-buy" rating in a research note on Thursday, May 8th. Finally, Barclays upped their target price on shares of Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a research report on Thursday, July 24th. Two research analysts have rated the stock with a hold rating, twenty-two have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, Boston Scientific currently has a consensus rating of "Buy" and a consensus target price of $117.50.

Boston Scientific Stock Performance

Shares of BSX stock traded up $0.26 during trading hours on Friday, hitting $103.22. The stock had a trading volume of 5,076,176 shares, compared to its average volume of 7,613,214. Boston Scientific Corporation has a twelve month low of $75.00 and a twelve month high of $108.94. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.88. The stock's 50 day moving average is $103.54 and its 200 day moving average is $102.07. The firm has a market capitalization of $152.95 billion, a PE ratio of 61.44, a PEG ratio of 2.48 and a beta of 0.66.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%. The firm had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. During the same quarter in the prior year, the business posted $0.62 earnings per share. Boston Scientific's revenue was up 22.8% compared to the same quarter last year. As a group, research analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Edward J. Ludwig sold 4,000 shares of the firm's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the sale, the director directly owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. This trade represents a 17.79% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $5,231,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares in the company, valued at $18,659,923.46. This represents a 21.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 345,029 shares of company stock valued at $35,976,603. 0.50% of the stock is owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.